Sadashiva Pai: How Pancreatic Cancer Uses Blood Clotting to Evade Immune Attack
Sadashiva Pai, Editorial Board at Aging Brain, Founder and CEO of Science Mission LLC, shared a post on LinkedIn:
“Pancreatic cancer uses blood-clotting system to evade immune attack
Pancreatic ductal adenocarcinoma is among the deadliest cancers, with a five-year survival rate of about 13 percent. While immunotherapies have transformed treatment for several cancers, they have shown little success against pancreatic cancer because the tumor environment can prevent immune cells from recognizing and attacking cancer cells.
The investigators identified two proteins produced by pancreatic cancer cells, PAI1 and PAI2, as key drivers of immune protection.
These proteins promote the buildup of fibrin, a protein normally involved in blood clotting and wound healing. The fibrin-rich environment attracts, educates, and retains macrophages, which can prevent cancer-fighting immune cells, including T cells, from reaching the tumor.
The findings shed light on how pancreatic cancer can resist immunotherapy and may also help explain why patients with pancreatic cancer are more susceptible to blood-clotting complications such as deep vein thrombosis. The findings suggest that tumors can increase blood clotting while suppressing immune activity.
One of the study’s most surprising findings was that these protective niches can be created by only a small fraction of tumor cells. In laboratory models, even when just 5 percent of implanted pancreatic cancer cells produced PAI1, they were able to reshape the surrounding immune environment, increasing immune-suppressing macrophages while reducing the number of activated T cells nearby.
The researchers also explored whether these immune-protective niches could be disrupted.
In multiple preclinical models, removing the genes responsible for producing PAI1 or PAI2, or blocking the pathway with an experimental drug, reduced immune suppression, slowed tumor growth, and significantly improved the effectiveness of anti-PD-1 immunotherapy.
Blocking interactions between fibrin and macrophages produced similar results.
Although additional research will be needed before these findings can be translated into treatments for patients, the study identifies several potential therapeutic targets that could eventually be combined with existing immunotherapies to improve outcomes for people with pancreatic cancer.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines